EGFR and neoplasm: Moreover, the proportions of CD107a+CD8+ T cells (Fig. 4G, Figs.S7F, S8F, S9F), GZMB+CD8+ T cells (Fig. 4H, Fig. S7G, S8G, Fig. S9G), and IFN-γ+CD8+ T cells (Fig. 4I, Figs. S7H, S8H, S9H) were significantly increased in the anti-TGF-β treatment group compared with the isotype control group, suggesting that TGF-β blockade enhanced the anti-tumor function of CD8+ T cells in the EGFR-mutated TME.